Promising future of breast cancer vaccine asking for multidisciplinary collaboration: a literature review DOI Creative Commons
Zhanyi Zhang, Mengyuan Li, Lei Zhang

и другие.

Frontiers in Cell and Developmental Biology, Год журнала: 2025, Номер 13

Опубликована: Апрель 24, 2025

Despite improved efficacy of breast cancer vaccine (BCV) made by multidisciplinary collaboration from fields such as materials science and computer science, clinical translation is still far satisfactory. Herein, we reviewed the evolution trajectory BCV summarized frontier topics challenges for achieving successful translation. Our analysis suggests that multi-omics immunoinformatics are increasingly being used to expand target repertoires, dedicated platforms facilitating precise spatiotemporal co-delivery epitopes immune modulators. has evolved towards delivery, strong properties, combined therapy. Clinical requires joint efforts experts in oncology, immunology, pharmacology, materials, science.

Язык: Английский

Chiral Aluminum Oxyhydroxide Supraparticles as Adjuvants DOI
Zongda Li,

Aihua Qu,

Chuanlai Xu

и другие.

Advanced Materials, Год журнала: 2025, Номер unknown

Опубликована: Апрель 16, 2025

Abstract Aluminum‐based adjuvants dominate global vaccine formulations owing to their proven efficacy in humoral immunity induction. However, inherent limitations activating cellular pose critical challenges for development. In this study, chiral flower‐like aluminum oxyhydroxide (AlOOH) supraparticles (SPs) are synthesized via a one‐pot hydrothermal method using cysteine (Cys) enantiomers as ligands, achieving g‐factor of 0.004. L‐AlOOH SPs (L‐SPs) demonstrate significantly greater enhancement dendritic cell (DC) maturation and antigen cross‐presentation efficiency compared D‐AlOOH (D‐SPs), indicating its potential an adjuvant. Mechanistic studies reveal that L‐SPs enter DCs Toll‐like receptor 2 (TLR2), thereby enhancing NOD‐like thermal protein domain associated 3 (NLRP3) inflammasome activation. vivo experiments show generate 21.59‐fold higher OVA‐specific antibody titers than commercial adjuvants. Further L‐SPs, after mixed with H9N2 virus proteins, enhance influenza by 15.28‐fold, sustained protection, confirming translational potential. This study demonstrates the performance AlOOH simultaneously amplify immunological responses, entering it promising next‐generation adjuvant cancer immunotherapy pandemic preparedness.

Язык: Английский

Процитировано

0
Promising future of breast cancer vaccine asking for multidisciplinary collaboration: a literature review DOI Creative Commons
Zhanyi Zhang, Mengyuan Li, Lei Zhang

и другие.

Frontiers in Cell and Developmental Biology, Год журнала: 2025, Номер 13

Опубликована: Апрель 24, 2025

Despite improved efficacy of breast cancer vaccine (BCV) made by multidisciplinary collaboration from fields such as materials science and computer science, clinical translation is still far satisfactory. Herein, we reviewed the evolution trajectory BCV summarized frontier topics challenges for achieving successful translation. Our analysis suggests that multi-omics immunoinformatics are increasingly being used to expand target repertoires, dedicated platforms facilitating precise spatiotemporal co-delivery epitopes immune modulators. has evolved towards delivery, strong properties, combined therapy. Clinical requires joint efforts experts in oncology, immunology, pharmacology, materials, science.

Язык: Английский

Процитировано

0